1 hour ago
1
Jonathan Ponciano, The Motley Fool
Wed, March 4, 2026 astatine 8:53 AM CST 4 min read
On February 17, 2026, Harvey Partners disclosed a caller presumption successful Balchem Corporation (NASDAQ:BCPC), acquiring 116,000 shares worthy $17.79 cardinal successful the 4th quarter.
-
This was a caller position; post-trade, Balchem Corporation represents 1.6% of Harvey Partners’ 13F reportable AUM of $1.13 billion.
-
Top holdings aft the filing:
-
NYSE: NPO: $53.4 cardinal (4.8% of AUM)
-
NASDAQ: GLDD: $48.6 cardinal (4.4% of AUM)
-
NASDAQ: MKSI: $46.2 cardinal (4.1% of AUM)
-
NASDAQ: ADEA: $45.1 cardinal (4.1% of AUM)
-
NASDAQ: LASR: $45.1 cardinal (4.1% of AUM)
-
-
As of February 17, 2026, shares of Balchem Corporation were priced astatine astir $180, up 8% implicit the past twelvemonth and trailing the S&P 500’s astir 16% gain.
| Price (as of February 17, 2026) | $180 |
| Market capitalization | $5.81 billion |
| Revenue (TTM) | $1.04 billion |
| Net income (TTM) | $154.85 million |
-
Balchem Corporation develops and markets specialty show ingredients for quality nutrition, carnal nutrition, and specialty chemic applications, with products including microencapsulated nutrients, nutrient and beverage systems, and sterilization agents.
-
The institution generates gross by supplying value-added ingredients and solutions to the food, pharmaceutical, carnal health, and concern sectors done nonstop sales, distributors, and agents.
-
It serves nutrient and beverage manufacturers, carnal provender producers, healthcare instrumentality companies, and cultivation clients successful the United States and internationally.
Balchem Corporation is simply a starring supplier of specialty ingredients and show products, operating astatine standard with implicit $1.0 cardinal successful trailing twelve-month gross and a diversified lawsuit base. The institution leverages precocious encapsulation and formulation technologies to present differentiated solutions for nutrition, health, and concern markets. Its wide merchandise portfolio and established beingness successful some quality and carnal nutrition supply a beardown competitory presumption wrong the specialty chemicals sector.
This determination adds a dependable compounder to a portfolio mostly tilted toward much cyclical concern and instrumentality names.
Balchem conscionable delivered grounds 2025 results, with nett income of $1 billion, up 8.8%, and nett net of $154.8 million, up 20.5%. Adjusted EBITDA reached $274.9 million, portion escaped currency travel deed a grounds $173.6 million. All 3 segments grew successful the 4th quarter, led by Human Nutrition and Health, and margins remained healthy, with gross borderline astatine 35.6% successful the 4th contempt immoderate input outgo pressure. With those results, it’s nary astonishment a money similar Harvey mightiness instrumentality interest, adjacent with shares up a lackluster 8% this past year.
Plus, the equilibrium expanse looks solid. Cash ended the twelvemonth astatine $74.6 million, outstanding revolver borrowings were $164 million, and nett indebtedness leverage was conscionable 0.3 times adjusted EBITDA. Management besides repurchased $107.6 cardinal of banal successful 2025 and accrued the dividend again.
The banal has lagged the broader marketplace but continues to softly compound earnings. Within a money that holds superior equipment, semiconductors, and dredging services, this astir 2% presumption adds a high-quality specialty ingredients level with pricing powerfulness and recurring demand. For semipermanent investors, the entreaty is durable maturation tied to nutrition and wellness trends alternatively than commodity cycles.
English (CA) · 
English (US) · 
Spanish (MX) ·